Meeting
2023 ASCO Annual Meeting
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.
Authors
Aaron Ciner
University of Maryland, Baltimore, MD
Aaron Ciner , Bach Ardalan , Yasmine Baca , Sourat Darabi , Anup Kasi , Emil Lou , Jose Ignacio Azqueta , Joanne Xiu , Chadi Nabhan , Anthony F. Shields , Andrew Aguirre , Harshabad Singh , Rachna T. Shroff , Michael J. Pishvaian , Sanjay Goel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4150)
DOI
10.1200/JCO.2023.41.16_suppl.4150
Abstract #
4150
Poster Bd #
471
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic indicators of KRAS G12X mutations in pancreatic cancer.
First Author: Bach Ardalan
Poster
2020 Gastrointestinal Cancers Symposium
Real-world patterns of care among patients with metastatic pancreatic cancer (mPC).
First Author: Eileen Mary O'Reilly
Poster
2018 Gastrointestinal Cancers Symposium
Clinical outcomes of FOLFIRINOX and gemcitabine/nab-paclitaxel in the real world setting.
First Author: Fernando Franco Franco
Poster
2018 Gastrointestinal Cancers Symposium
Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.
First Author: Inhwang Hwang